Toggle Main Menu Toggle Search

Open Access padlockePrints

How Can We Treat Mitochondrial Encephalomyopathies? Approaches to Therapy

Lookup NU author(s): Professor Rita HorvathORCiD, Professor Grainne Gorman, Professor Patrick Chinnery


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Mitochondrial disorders are a heterogeneous group of diseases affecting different organs (brain, muscle, liver, and heart), and the severity of the disease is highly variable. The chronicity and heterogeneity, both clinically and genetically, means that many patients require surveillance follow-up over their lifetime, often involving multiple disciplines. Although our understanding of the genetic defects and their pathological impact underlying mitochondrial diseases has increased over the past decade, this has not been paralleled with regards to treatment. Currently, no definitive pharmacological treatment exists for patients with mitochondrial dysfunction, except for patients with primary deficiency of coenzyme Q10. Pharmacological and nonpharmacological treatments increasingly being investigated include ketogenic diet, exercise, and gene therapy. Management is aimed primarily at minimizing disability, preventing complications, and providing prognostic information and genetic counseling based on current best practice. Here, we evaluate therapies used previously and review current and future treatment modalities for both adults and children with mitochondrial disease. © 2008 The American Society for Experimental NeuroTherapeutics, Inc.

Publication metadata

Author(s): Horvath R, Gorman G, Chinnery PF

Publication type: Article

Publication status: Published

Journal: Neurotherapeutics

Year: 2008

Volume: 5

Issue: 4

Pages: 558-568

ISSN (print): 1933-7213

ISSN (electronic): 1545-5351

Publisher: Elsevier Inc.


DOI: 10.1016/j.nurt.2008.07.002


Altmetrics provided by Altmetric


Funder referenceFunder name
MC_G0802536Medical Research Council